Key result
Apixaban causes a concentration-dependent prolongation of aPTT, PT, and dilute PT, but specific FXa chromogenic assays are required for accurate pharmacodynamic estimation.
Why the study?
Which coagulation assays can accurately assess the pharmacodynamic effect of apixaban in platelet-poor plasma?
Population
Platelet-poor plasma
Design
Preclinical
Authors
Loading...
Hypothesis-generating for FXa chromogenic preference in apixaban monitoring; requires human validation before clinical adoption.
Which coagulation assays can accurately assess the pharmacodynamic effect of apixaban in platelet-poor plasma?
Specific chromogenic FXa assays, rather than routine PT or aPTT, are required to accurately assess the pharmacodynamic effects of apixaban.
Chatelain et al. (2013) studied this question. Apixaban was evaluated on Impact of apixaban on routine and specific coagulation assays. Apixaban causes a concentration-dependent prolongation of aPTT, PT, and dilute PT, but specific FXa chromogenic assays are required for accurate pharmacodynamic estimation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: